---
title: "Regen BioPharma, Inc. (RGBP.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/RGBP.US.md"
symbol: "RGBP.US"
name: "Regen BioPharma, Inc."
industry: "Biotechnology"
---

# Regen BioPharma, Inc. (RGBP.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [regenbiopharmainc.com](https://regenbiopharmainc.com) |

## Company Profile

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:14.000Z

**Overall: C (0.52)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 178 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -39.53% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -0.03 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 169935.65 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 236561.00 |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 28.19% | A |
| Profit Margin | -730.03% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | -39.53% | D |
| Total Assets YoY | 23.85% | A |
| Net Assets YoY | -15.74% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -13.70% | D |
| OCF YoY | 0.00% | C |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.10 | A |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 2872.53% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Regen BioPharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "28.19%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-730.03%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-39.53%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "23.85%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-15.74%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-13.70%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.10",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "2872.53%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.10 | 84/604 | - | - | - |
| PB | -0.03 | 456/604 | - | - | - |
| PS (TTM) | 0.72 | 13/604 | 5.47 | 4.01 | 2.62 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/RGBP.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/RGBP.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/RGBP.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.